In this episode, we speak to Dr Lauren Macdonald, a psychiatrist, psychedelic therapist, and group retreat facilitator. She details her path to psychedelics, in particular her cancer diagnosis that left her with existential dread that she felt fully dissipate only after a psychedelic experience. She goes on to discuss her interest in group retreats and treating existential distress. Before closing, she explains problems with the current medical model in the UK and where psychedelics fit.

LINK TO THE 2026 RETURNING TO WHOLENESS RETREAT

Links
Psilocybin
Imperial Centre for Psychedelic Research
Essence Medicine
Psilocybin and Cancer-Related Distress 

Join us in this episode as Prof Nutt speaks to Prof Mark Solms, a leading expert on Freud and author of the new book The Only Cure. Mark details his early fascination with neuropsychology that led him to study the neurological underpinnings of sleep and dreams. He explains how some of his own research lent more credence to Freud’s claims and deepened his interest in psychoanalysis. Mark concludes by discussing what the only cure symbolizes: talking therapies that address the root causes of psychopathology, as opposed to treatments that mask the symptoms.

Links

●      Prof Mark Solms

●      The Only Cure

●      PET Sleep Scan

●      Dreaming Study

●      MDMA

Join us in this episode as we speak to Dr Harriet de Witt, professor of psychiatry and neuropharmacology at the University of Chicago. She shares how she fell in love with the field, studying the animal model of self-administration, and how that work fed into her later research with human participants. As a leading expert on the pharmacology of MDMA, she explores the subtle differences between amphetamine and MDMA, before talking about the results from both her MDMA and LSD studies.

Links

●      UChicago Profile

●      Amphetamine

●      MDMA

●      LSD

●      MDMA/Amphetamine/Alcohol Sociality Study

●      LSD Microdosing & Emotionality Study

Join us in this episode as we speak to Dr. Rachel Andrews, an addiction and harm reduction researcher at the University of Bath, and Hannah Dawes, a PSHE teacher and the creator of the podcast The Exchange. The conversation focuses on the prevalence of vaping in schools, particularly exploring the ways in which vapes have been marketed to children and the patterns of use in schools. Rachel provides data from her team’s analysis of that shows what’s really in the vapes students are using, while Hannah lends her perspective within schools, explaining how a supportive approach to students using vapes is more successful than punitive measures.

Links

Nicotine

Drug Science Blog

Spice

Cannabis

Teaching About Nicotine and Vaping

Daniel Spargo-Mabbs Foundation

The Exchange
Spice Comic 

In this episode of the Drug Science Podcast, Prof Nutt speaks with Erica Rex, author of the book Seeing What is There, which explores the complex history of psychedelic therapy. She shares her own experiences with psychedelic-assisted therapy, while providing context on the guardrails that are necessary for these treatments to maximize benefits and minimize harms. Viewing psychedelics as therapeutic accelerants, Erica speaks on the current state of mental health treatments and explores how complex trauma and other mental health problems could be better treated.

Erica Instagram
Erica Substack 

Links

●      Seeing What is There

●      The Culture Is the Poison: Why Psychedelics Are Dangerous Medicine in a Neoliberal Society

●      Psilocybin

●      MDMA

●      5-MeO-DMT

●      More From Erica

In this episode, we’re joined by Justin Smith-Ruiu, a philosopher at Université Paris Cité and the author of On Drugs. He discusses his motivations behind the book, rooted in his early experiences with psychedelics and the many cultural roles he has seen them play across different contexts. As the conversation unfolds, Smith-Ruiu reflects on his decision to quit drinking in favor of psychedelics and the profound positive changes that choice has brought to his life.

Links

Justin Smith-Ruiu

On Drugs

Psilocybin

Join us in this episode as we talk to Robert Schoevers, a professor of psychiatry at the University of Groningen and one of the pioneers of psychedelic-assisted therapy. He explains why human complexity led him to psychiatry, begoring discussing how his early psychedelic research into esketamine aimed to meet the unmet needs of treatment-resistant patients. Schoevers goes on to explore the ways in which his approach to ketamine-assisted therapy has transitioned over time and has led him to lead bigger projects, like the EU-funded palliative care project, PsyPal.

Links

Profile

Ketamine

Compass Paper

PsyPal

Join us in this episode as we speak with Emma Robinson, a professor of psychopharmacology at the University of Bristol with extensive experience in animal research. She unpacks the regulations surrounding animal research, offering a scientist’s view on animal rights activism, ethical tension, and why this work remains essential. Robinson also delves into the emerging intersection of psychedelics and animal research, describing how these substances are studied and how they might help reshape mental illness.

• Professor Emma Robinson
• UK Government’s Roadmap to Ending Animal Testing
• PETA Confrontation
• Cognitive and affective models of psychedelics in rodents
• Psilocybin
• Ketamine
• British Neuroscience lecture with Prof Robinson and Prof Nutt
• The 3Hs Initiative

In this episode of the Drug Science Podcast, we talk to Simon Doherty, a journalist and content creator with a focus on harm reduction. He explores how reporting on electronic music and rave culture naturally led to his work on harm reduction. He goes on to dissect Talk to Frank and its flaws in providing accurate, evidence-based information. Finally, by comparing the unique landscape of free parties to the regulated club scene, Doherty discusses why and how clubs avoid common sense harm reduction techniques, endangering clubgoers.

Links

• Simon’s TikTok
• Investigating Talk to Frank
• Calling Frank
• The Loop
• Rave Aid Crew
• GHB/GHL
• Ketamine
• Nitazenes

Join us in this episode as we talk to Prof Sara Tai, a professor of clinical psychology at the University of Manchester and an NHS consultant clinical psychologist. 

Sara’s research is grounded in biopsychosocial frameworks, with a focus on understanding the mechanisms of change that underpin effective psychological therapies. She has extensive experience delivering therapy, and training other clinicians to deliver interventions with individuals, families, and young people across diverse settings, including acute in-patient units, community mental health services, and schools.

For many years, Sara has been at the forefront of research into psychedelic-assisted therapies, working collaboratively with academic and industry partners to explore how psychedelics bring about therapeutic change. She has been instrumental in manualising psychological support models that integrate the core effective components shared across evidence-based psychotherapies, helping to define best practice in this rapidly advancing area. An experienced researcher, clinician, and trainer, Sara has led and collaborated on large-scale randomised controlled trials and has played a central role in training psychedelic therapists worldwide. Her work continues to bridge scientific research and clinical practice, advancing safe, effective, and compassionate approaches to mental health care.

Sara explores her research into the oft-overlooked role of therapy within psychedelic treatments. She discuses how her work has helped to challenge the notion of psychedelic compounds as medicine in themselves, shifting the focus onto the therapeutic approaches alongside them. Ultimately, Sara underscores the need for more transformative psychedelic experiences grounded in peer support, indigenous knowledge, or therapeutic experience in order to facilitate positive outcomes. 

Links

Prof Sara Tai

Cognitive Behavioural Therapy

Acceptance and Commitment Therapy 

Method of Levels